Table 2.
Adverse event | Grade 3 | Grade 4 |
---|---|---|
Thrombocytopenia | 4 (11%) | 0 |
Anemia | 2 (6%) | 0 |
Diarrhea | 2 (6%) | 0 |
Fatigue | 2 (6%) | 0 |
Rash/Desquamation | 1 (3%) | 0 |
Thrombosis | 0 | 2 (6%) |
Hepatic failure | 0 | 1 (3%) |
SGOT (AST) | 3 (9%) | 0 |
SGPT (ALT) | 2 (6%) | 0 |
Hyponatremia | 2 (6%) | 0 |
Ileus | 1 (3%) | 0 |
Hyperglycemia | 1 (3%) | 0 |
Hypoglycemia | 0 | 1 (3%) |
Hypotension | 1 (3%) | 0 |
Muscle weakness | 1 (3%) | 0 |
Dizziness | 1 (3%) | 0 |
Cognitive disorder | 1 (3%) | 0 |
NCI CTCAE V3.0. Reported are AEs deemed at least possibly related to BORTEZOMIB